In addition to cholestasis, FXR antagonism might have pharmacological and clinical relevance in several human disorders, including cancers of the esophagus, stomach and pancreas which express high levels of FXR and whose proliferation is driven by bile acids in a FXR-dependent manner [18]. The gene discussed is NR1H4; the disease is cholestasis.